Overview

Efficacy and Safety of Apatinib As Third Line Therapy in Patients With Advanced Ovarian Cancer

Status:
Unknown status
Trial end date:
2021-02-01
Target enrollment:
Participant gender:
Summary
The study is to investigate the efficacy and safety of apatinib in patients with advanced ovarian cancer,who has received second-line chemotherapy and failed.
Phase:
Phase 2
Details
Lead Sponsor:
Sichuan Cancer Hospital and Research Institute
Treatments:
Apatinib